15Toxoplasma gondii and related human parasites contain an essential plastid 16 organelle called the apicoplast. Clinically-used antibiotics and other inhibitors that 17 disrupt apicoplast biogenesis cause a mysterious "delayed-death" phenotype, in which 18 parasite growth is unaffected during the first lytic cycle of inhibitor treatment but is 19 severely inhibited in the second lytic cycle even after drug removal. Critical to 20 understanding the complex downstream cellular effects of these drug classes is the timing 21 of apicoplast loss during inhibitor treatment and how it relates to this peculiar growth 22phenotype. Here we show that, upon treatment with diverse classes of apicoplast 23 . CC-BY-NC-ND 4.0 International license It is made available under a was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which . http://dx.doi.org/10.1101/384123 doi: bioRxiv preprint first posted online Aug. 3, 2018; 2 inhibitors, newly-replicated T. gondii parasites in the first lytic cycle initially form 24 apicoplasts with defects in protein import or genome replication and eventually fail to 25 inherit the apicoplast altogether. Despite the accumulation of parasites with defective or 26 missing apicoplasts, growth is unaffected during the first lytic cycle, as previously 27 observed. Strikingly, concomitant inhibition of host cell isoprenoid biosynthesis results in 28 growth inhibition in the first lytic cycle and unmasks the apicoplast defects. These results 29 suggest that defects in and even complete loss of the apicoplast in T. gondii are partially 30 rescued by scavenging of host cell metabolites leading to death that is delayed. Our 31 findings uncover host cell interactions that can alleviate apicoplast inhibition and 32 highlight key differences in "delayed-death" inhibitors between T. gondii and 33
Plasmodium falciparum. 34 35Introduction 36